Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00851929 · ClinicalTrials.gov registry record · Phase 2
Ambrisentan (Letairis) for Sarcoidosis Associated Pulmonary Hypertension
A Phase 2 study of Pulmonary Hypertension and Sarcoidosis, sponsored by Medical University of South Carolina.
- Completed
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
- 2
- Study locations
NCT00851929 is a Phase 2 study of Pulmonary Hypertension and Sarcoidosis that has completed, run by Medical University of South Carolina. The registered enrollment target is 16 participants, below the 613-participant average among 72 other Pulmonary Hypertension trials with a reported enrollment target (97% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT00851929, a Phase 2 study of Pulmonary Hypertension and Sarcoidosis, has completed, sponsored by Medical University of South Carolina.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
- 2
- Study locations
Study Summary
Hypothesis: Ambrisentan (Letairis ®) is safe and effective in treating pulmonary hypertension in patients with Sarcoidosis
Conditions Studied
Interventions
- DRUG Ambrisentan
Study Locations (2)
North Carolina
- University of North Carolina Medical Center - Chapel Hill
South Carolina
- Medical Univerrsity of South Carolina - Charleston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2008-11 |
| Est. Completion | 2011-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00851929
The ClinicalTrials.gov registry entry for NCT00851929 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 613-participant average among 72 other Pulmonary Hypertension trials with a reported enrollment target (97% lower). The listed sponsor is Medical University of South Carolina, which has 755 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Pulmonary Hypertension appearing as the primary indexed condition, and to 1 intervention - of which Ambrisentan is the first listed.
NCT00851929 reports 2 study locations spanning 2 distinct geographic areas - top geographies include North Carolina, South Carolina.
Frequently Asked Questions
What is clinical trial NCT00851929 about?
NCT00851929 is a clinical study titled "Ambrisentan (Letairis) for Sarcoidosis Associated Pulmonary Hypertension". Hypothesis: Ambrisentan (Letairis ®) is safe and effective in treating pulmonary hypertension in patients with Sarcoidosis
What is the current status of trial NCT00851929?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2008-11. Estimated completion is 2011-11.
What conditions does trial NCT00851929 study?
This clinical trial studies the following conditions: Pulmonary Hypertension, Sarcoidosis.
What interventions are being tested in trial NCT00851929?
The interventions under investigation include: Ambrisentan (DRUG).
Who is sponsoring clinical trial NCT00851929?
This trial is sponsored by Medical University of South Carolina, which has 755 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00851929 being conducted?
This trial has 2 study locations across North Carolina, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Trial of Phosphodiesterase-5 Inhibitor in Neonatal Congenital Diaphragmatic Hernia (TOP-CDH)
RECRUITING · Phase 2
-
Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis
RECRUITING · Phase 2
-
Xenon MRI Pulm Hypertension
RECRUITING · Phase 2
-
A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD
RECRUITING · Phase 2
-
A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study)
RECRUITING · Phase 2
-
Metformin for Pulmonary Hypertension HFpEF
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.